ESMO 2014: Merck's Keytruda and B-MS' Opdivo

30 September 2014
2019_biotech_test_vial_discovery_big

Early results from pharma giant Merck & Co (NYSE: MRK) on the use of its Keytruda (pembrolizumab) in patients with advanced bladder cancer were presented at European Society for Medical Oncology’s congress in Madrid.

The data showed that Keytruda as a monotherapy achieved 24% overall response rate in patients with PD-L1 positive, advanced bladder cancer, and the company is planning a Phase III study in the indication to start before the end of the year.

Alise Reicin, vice president of oncology at Merck Research Laboratories, said: “Although at this stage the dataset is small, we are encouraged by the response rate, complete response rate, and the durability of the response in patients suffering from advanced bladder cancer. As communicated previously, based on these data Merck will initiate a Phase III study this year to better understand the potential of Keytruda in advanced bladder cancer.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology